Description: During the past few years, performance, cost, and risk trends for Medigap products have undergone substantial changes. Some of these trends could ease cost pressures on Medigap insurers, while others might increase them. Part 1 of this Issue Brief article discusses current changing trends and considerations around about how they are impacting Medigap.

Description: Prescription drug affordability remains a critical concern for consumers, payers and policymakers alike. This paper discusses an alternative to policy solutions: reimagining commercial pharmacy financing using a value-based reimbursement model to increase transparency, encourage pharmaceutical competition, align stakeholder incentives and mitigate total cost of care (TCOC) increases.

Description: This report focuses on the risks of change in the insurance industry and adapting to the "New" New Normal. It includes survey results, analysis, and discussions on various risks affecting the industry in the current environment.

Description: Read this essay, which addresses the actuarial impact of mental health issues in retirement.

Description: The Society of Actuaries Research Institute developed a new study to explore pharmacy financing. The goals of the SOA related to this research are to identify opportunities to increase transparency, encourage competition, align stakeholder incentives and mitigate increases in total cost of care. The research uses a value-based methodology.

Description: A call for project proposals to study the impacts of climate-induced migration on various areas which can influence the delivery of services and availability of insurance coverages.

Description: At the end of December 2020, Congress enacted the Consolidated Appropriates Act, 2021, which included revisions to Section 7702. Effective for policies issued after December 31, 2020, the fixed 4% and 6% minimum annual effective rates under these tests were changed to refer to a market-based rate called the “insurance interest rate”. For contracts issued in 2021, the insurance rate was set to 2% - defined as the lower of the Section 7702 applicable federal interest rate based on the 60-month period ending December 2019 (2%) and the Section 7702 valuation interest rate in effect for 2020 (3.5%). This reduction in the rates used for compliance testing required significant product, operational, and technology changes for companies to reach product compliance. After 2021, the insurance interest rate is redetermined annually with a minimum change floor.

Description: Prescription drug affordability remains a critical concern for consumers, payers and policymakers alike. This paper discusses an alternative to policy solutions: reimagining commercial pharmacy financing using a value-based reimbursement model to increase transparency, encourage pharmaceutical competition, align stakeholder incentives and mitigate total cost of care (TCOC) increases.

Description: Boost your actuarial career and learn about the SOA, the word's largest actuarial society. This webcast is designed for Spanish/Portuguese speaking audiences.